Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes

Diabetologia

Volumn 56, Issue 2, 2013, Pages 323-329

  Alkayyali, S ^a   Lajer, M ^b   Deshmukh, H ^c   Ahlqvist, E ^a   Colhoun, H ^c   Isomaa, B ^d,e   Rossing, P ^b   Groop, L ^a,f   Lyssenko, V ^a  

^a LUND UNIVERSITY   (Sweden)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d FOLKHÄLSAN RESEARCH CENTER   (Finland)

^e Department of Social Service and Health Care ^*  (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diabetes complications; HMGA2; Nephropathy; SNP; Type 2 diabetes

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE REGISTRY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HIGH MOBILITY GROUP A2 PROTEIN GENE; HUMAN; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HMGA2 PROTEIN; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

MLCS; MLOWN;

EID: 84878783069     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2760-5     Document Type: Article

References (36)

1. Chin MT, Pellacani A, Wang H et al (1998) Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J Biol Chem 273:9755-9760
2. Forbes JM, Fukami K, Cooper ME (2007) Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115:69-84
3. Parving HH (2001) Diabetic nephropathy: prevention and treatment. Kidney Int 60:2041-2055
4. Harris MI, Flegal KM, Cowie CC et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518-524
5. Di Landro D, Catalano C, Lambertini D et al (1998) The effect of metabolic control on development and progression of diabetic nephropathy. Nephrol Dial Transplant 13(Suppl 8):35-43
6. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
7. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
8. Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100
9. Fioretto P, Mauer M, Brocco E et al (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569-1576
10. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 354:2473-2483
11. Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449-2454
12. Billings LK, Florez JC (2010) The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 1212:59-77
13. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983-989
14. Ahluwalia TS, Lindholm E, Groop LC (2011) Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 54:2295-2302
15. Alkhalaf A, Zurbig P, Bakker SJ et al (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 5:e13421
16. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266
17. Wong TY, Choi PC, Szeto CC et al (2002) Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 25:900-905
18. Morris AD, Boyle DI, MacAlpine R et al (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524-528
19. Peterson B, Trell E, Kristenson H (1983) Comparison of gamma-glutamyltransferase and questionnaire test as alcohol indicators in different risk groups. Drug Alcohol Depend 11:279-286
20. Berglund G, Nilsson P, Eriksson KF et al (2000) Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 247:19-29
21. Groop L, Forsblom C, Lehtovirta M et al (1996) Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585-1593
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
23. Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579-589
24. Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105-116
25. Saxena R, Hivert MF, Langenberg C et al (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142-148
26. Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638-645
27. Yasuda K, Miyake K, Horikawa Y et al (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40:1092-1097
28. Kottgen A, Pattaro C, Boger CA et al (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42:376-384
29. McDonough CW, Palmer ND, Hicks PJ et al (2011) A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int 79:563-572
30. Bianchi ME, Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15:496-506
31. Reeves R, Beckerbauer L (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519:13-29
32. Li O, Vasudevan D, Davey CA, Droge P (2006) High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 44:523-529
33. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899-910
34. Persson F, Andren Y, Winnes M et al (2009) High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Gene Chromosome Canc 48:69-82
35. Fedele M, Battista S, Kenyon L et al (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190-3198
36. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174:175-183